Cargando…

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France

OBJECTIVES: To identify switch modalities used when initiating second- or third-line anagrelide for essential thrombocythemia (ET), assess whether anagrelide is initiated consistently with Summary of Product Characteristics (SPC) recommendations, and determine whether different observed switch regim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rey, Jérôme, Viallard, Jean-François, Keddad, Karim, Smith, Jonathan, Wilde, Paul, Kiladjian, Jean-Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232889/ https://www.ncbi.nlm.nih.gov/pubmed/24118452 http://dx.doi.org/10.1111/ejh.12210

Ejemplares similares

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
por: Birgegård, Gunnar
Publicado: (2016)

Anagrelide‐induced pericardial effusion in a patient with essential thrombocythemia
por: Song, David, et al.
Publicado: (2023)

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting
por: Ito, Tomoki, et al.
Publicado: (2019)

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
por: Birgegård, Gunnar, et al.
Publicado: (2018)

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders
por: Palmblad, Jan, et al.
Publicado: (2008)

Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review
por: Sugawara, Masafumi, et al.
Publicado: (2022)

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
por: Cascavilla, Nicola, et al.
Publicado: (2015)

Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report
por: Lim, Young-Hyo, et al.
Publicado: (2010)

Leg Ulcers Associated with Anagrelide
por: Oskay, Tuba, et al.
Publicado: (2021)

Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose
por: Komatsu, Norio, et al.
Publicado: (2022)

A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment
por: Byun, Ja Min, et al.
Publicado: (2022)

Anagrelide-Induced Supraventricular Tachycardia: A Case Report
por: Badar, Faraz, et al.
Publicado: (2022)

S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY
por: Passamonti, Francesco, et al.
Publicado: (2023)

Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia
por: Gotic, Mirjana, et al.
Publicado: (2020)

Essential thrombocythemia
por: Brière, Jean B
Publicado: (2007)

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide
por: Gaitanis, Georgios, et al.
Publicado: (2018)

Mycobacterium microti Infection in Red Foxes in France
por: Michelet, Lorraine, et al.
Publicado: (2021)

Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia
por: Tosetto, Alberto, et al.
Publicado: (2021)

Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?
por: Cattaneo, Marco
Publicado: (2023)

Mycobacterium bovis Infection of Red Fox, France
por: Michelet, Lorraine, et al.
Publicado: (2018)

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review
por: Ianotto, Jean-Christophe, et al.
Publicado: (2019)

Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets
por: Miyashita, Naohiro, et al.
Publicado: (2019)

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
por: Le Calloch, Ronan, et al.
Publicado: (2018)

Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high‐risk essential thrombocythemia
por: Park, Young Hoon, et al.
Publicado: (2023)

Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice
por: Amé, Shanti, et al.
Publicado: (2023)

Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Anagrelide Hydrochloride
por: Pujeri, Sudhakar S., et al.
Publicado: (2012)

Cardiovascular Safety of Anagrelide in Healthy Subjects: Effects of Caffeine and Food Intake on Pharmacokinetics and Adverse Reactions
por: Martínez-Sellés, Manuel, et al.
Publicado: (2012)

Management of thrombocythemia
por: Gowin, Krisstina, et al.
Publicado: (2014)

Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2012)

Coexistence of Essential Thrombocythemia, Iron-Refractory Iron Deficiency Anemia and Renal Cell Carcinoma
por: Namdaroğlu, Sinem, et al.
Publicado: (2016)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Mycobacterium bovis Infection in Red Foxes in Four Animal Tuberculosis Endemic Areas in France
por: Richomme, Céline, et al.
Publicado: (2020)

Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy
por: Treliński, Jacek, et al.
Publicado: (2012)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Pharmacokinetics of a Novel Anagrelide Extended‐Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product
por: Petrides, Petro E., et al.
Publicado: (2017)

Serological and molecular survey of Leptospira spp. infections in wild boars and red foxes from Southeastern France
por: Roquelo, Cédric, et al.
Publicado: (2021)

Westward Spread of Echinococcus multilocularis in Foxes, France, 2005–2010
por: Combes, Benoît, et al.
Publicado: (2012)

RadioLigand Therapy with [(177)Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
por: Terroir, Marie, et al.
Publicado: (2023)

Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial
por: Ureña-Torres, Pablo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4lj2ar1uvubpei8bs1d0u8aav4